Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study
Background: Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for longterm dutasteride use in AGA is lacking. Objective: To describe baseline characteristics, treatment patterns and long-term safety and ef...
Gespeichert in:
| Veröffentlicht in: | Annals of dermatology 2022-10, Vol.34 (5), p.349 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | kor |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 349 |
| container_title | Annals of dermatology |
| container_volume | 34 |
| creator | Gwang-seong Choi Woo-young Sim Hoon Kang Chang Hun Huh Yang Won Lee Sumitra Shantakumar Yu-fan Ho Eun-jeong Oh Mei Sheng Duh Wendy Y. Cheng Priyanka Bobbili Philippe Thompson-leduc Gary Ong |
| description | Background: Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for longterm dutasteride use in AGA is lacking.
Objective: To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride.
Methods: This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness (improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period.
Results: Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (p |
| format | Article |
| fullrecord | <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_3971421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>3971421</kiss_id><sourcerecordid>3971421</sourcerecordid><originalsourceid>FETCH-kiss_primary_39714213</originalsourceid><addsrcrecordid>eNp9i8FKw0AURQdRMFq_wM37gcBM0prGXagtghbEdF-G5KV9ms6UeW9S8jX-qhXEpasL55x7oZJM61maz8vppUqMNnla6nlxrW6YP7R-MFlhEvX16t0u3WA4wLLrsBEa0CEzWNdCbTuUEXwHT1EsCwZqEQYMHBlW5P4QOXizQuiE4USyh7XtESrXBr9DRw1UvT9iQ_anrH08Fy8-oH2ECtaxF2rO14Cw2Nsg8I4D4Qlqie04UVed7RnvfvdW3a-Wm8Vz-knM22Oggw3jNi8LM81M_r_9BrNEVxo</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study</title><source>KoreaMed Synapse</source><source>KoreaMed Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Gwang-seong Choi ; Woo-young Sim ; Hoon Kang ; Chang Hun Huh ; Yang Won Lee ; Sumitra Shantakumar ; Yu-fan Ho ; Eun-jeong Oh ; Mei Sheng Duh ; Wendy Y. Cheng ; Priyanka Bobbili ; Philippe Thompson-leduc ; Gary Ong</creator><creatorcontrib>Gwang-seong Choi ; Woo-young Sim ; Hoon Kang ; Chang Hun Huh ; Yang Won Lee ; Sumitra Shantakumar ; Yu-fan Ho ; Eun-jeong Oh ; Mei Sheng Duh ; Wendy Y. Cheng ; Priyanka Bobbili ; Philippe Thompson-leduc ; Gary Ong</creatorcontrib><description>Background: Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for longterm dutasteride use in AGA is lacking.
Objective: To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride.
Methods: This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness (improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period.
Results: Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (p<0.001) and more likely to have moderate/ severe BASP classification at baseline (p=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, n=285), dutasteride-treated patients showed greater improvement in hair growth than finasteride-treated patients, as measured by the BASP basic M classification (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; p=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observation period were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%; p=0.201), although reports of AEs of special interest were equivalent (p<0.001).
Conclusion: Dutasteride showed greater effectiveness than finasteride in improving BASP classification in treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.</description><identifier>ISSN: 1013-9087</identifier><identifier>EISSN: 2005-3894</identifier><language>kor</language><publisher>대한피부과학회</publisher><subject>Alopecia ; Androgenic alopecia ; Dutasteride ; Epidemiology ; Finasteride ; Retrospective studies</subject><ispartof>Annals of dermatology, 2022-10, Vol.34 (5), p.349</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Gwang-seong Choi</creatorcontrib><creatorcontrib>Woo-young Sim</creatorcontrib><creatorcontrib>Hoon Kang</creatorcontrib><creatorcontrib>Chang Hun Huh</creatorcontrib><creatorcontrib>Yang Won Lee</creatorcontrib><creatorcontrib>Sumitra Shantakumar</creatorcontrib><creatorcontrib>Yu-fan Ho</creatorcontrib><creatorcontrib>Eun-jeong Oh</creatorcontrib><creatorcontrib>Mei Sheng Duh</creatorcontrib><creatorcontrib>Wendy Y. Cheng</creatorcontrib><creatorcontrib>Priyanka Bobbili</creatorcontrib><creatorcontrib>Philippe Thompson-leduc</creatorcontrib><creatorcontrib>Gary Ong</creatorcontrib><title>Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study</title><title>Annals of dermatology</title><addtitle>Annals of Dermatology</addtitle><description>Background: Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for longterm dutasteride use in AGA is lacking.
Objective: To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride.
Methods: This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness (improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period.
Results: Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (p<0.001) and more likely to have moderate/ severe BASP classification at baseline (p=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, n=285), dutasteride-treated patients showed greater improvement in hair growth than finasteride-treated patients, as measured by the BASP basic M classification (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; p=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observation period were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%; p=0.201), although reports of AEs of special interest were equivalent (p<0.001).
Conclusion: Dutasteride showed greater effectiveness than finasteride in improving BASP classification in treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.</description><subject>Alopecia</subject><subject>Androgenic alopecia</subject><subject>Dutasteride</subject><subject>Epidemiology</subject><subject>Finasteride</subject><subject>Retrospective studies</subject><issn>1013-9087</issn><issn>2005-3894</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9i8FKw0AURQdRMFq_wM37gcBM0prGXagtghbEdF-G5KV9ms6UeW9S8jX-qhXEpasL55x7oZJM61maz8vppUqMNnla6nlxrW6YP7R-MFlhEvX16t0u3WA4wLLrsBEa0CEzWNdCbTuUEXwHT1EsCwZqEQYMHBlW5P4QOXizQuiE4USyh7XtESrXBr9DRw1UvT9iQ_anrH08Fy8-oH2ECtaxF2rO14Cw2Nsg8I4D4Qlqie04UVed7RnvfvdW3a-Wm8Vz-knM22Oggw3jNi8LM81M_r_9BrNEVxo</recordid><startdate>20221005</startdate><enddate>20221005</enddate><creator>Gwang-seong Choi</creator><creator>Woo-young Sim</creator><creator>Hoon Kang</creator><creator>Chang Hun Huh</creator><creator>Yang Won Lee</creator><creator>Sumitra Shantakumar</creator><creator>Yu-fan Ho</creator><creator>Eun-jeong Oh</creator><creator>Mei Sheng Duh</creator><creator>Wendy Y. Cheng</creator><creator>Priyanka Bobbili</creator><creator>Philippe Thompson-leduc</creator><creator>Gary Ong</creator><general>대한피부과학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20221005</creationdate><title>Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study</title><author>Gwang-seong Choi ; Woo-young Sim ; Hoon Kang ; Chang Hun Huh ; Yang Won Lee ; Sumitra Shantakumar ; Yu-fan Ho ; Eun-jeong Oh ; Mei Sheng Duh ; Wendy Y. Cheng ; Priyanka Bobbili ; Philippe Thompson-leduc ; Gary Ong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_39714213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2022</creationdate><topic>Alopecia</topic><topic>Androgenic alopecia</topic><topic>Dutasteride</topic><topic>Epidemiology</topic><topic>Finasteride</topic><topic>Retrospective studies</topic><toplevel>online_resources</toplevel><creatorcontrib>Gwang-seong Choi</creatorcontrib><creatorcontrib>Woo-young Sim</creatorcontrib><creatorcontrib>Hoon Kang</creatorcontrib><creatorcontrib>Chang Hun Huh</creatorcontrib><creatorcontrib>Yang Won Lee</creatorcontrib><creatorcontrib>Sumitra Shantakumar</creatorcontrib><creatorcontrib>Yu-fan Ho</creatorcontrib><creatorcontrib>Eun-jeong Oh</creatorcontrib><creatorcontrib>Mei Sheng Duh</creatorcontrib><creatorcontrib>Wendy Y. Cheng</creatorcontrib><creatorcontrib>Priyanka Bobbili</creatorcontrib><creatorcontrib>Philippe Thompson-leduc</creatorcontrib><creatorcontrib>Gary Ong</creatorcontrib><collection>Korean Studies Information Service System (KISS)</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Annals of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gwang-seong Choi</au><au>Woo-young Sim</au><au>Hoon Kang</au><au>Chang Hun Huh</au><au>Yang Won Lee</au><au>Sumitra Shantakumar</au><au>Yu-fan Ho</au><au>Eun-jeong Oh</au><au>Mei Sheng Duh</au><au>Wendy Y. Cheng</au><au>Priyanka Bobbili</au><au>Philippe Thompson-leduc</au><au>Gary Ong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study</atitle><jtitle>Annals of dermatology</jtitle><addtitle>Annals of Dermatology</addtitle><date>2022-10-05</date><risdate>2022</risdate><volume>34</volume><issue>5</issue><spage>349</spage><pages>349-</pages><issn>1013-9087</issn><eissn>2005-3894</eissn><abstract>Background: Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for longterm dutasteride use in AGA is lacking.
Objective: To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride.
Methods: This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness (improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period.
Results: Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (p<0.001) and more likely to have moderate/ severe BASP classification at baseline (p=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, n=285), dutasteride-treated patients showed greater improvement in hair growth than finasteride-treated patients, as measured by the BASP basic M classification (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; p=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observation period were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%; p=0.201), although reports of AEs of special interest were equivalent (p<0.001).
Conclusion: Dutasteride showed greater effectiveness than finasteride in improving BASP classification in treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.</abstract><pub>대한피부과학회</pub><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1013-9087 |
| ispartof | Annals of dermatology, 2022-10, Vol.34 (5), p.349 |
| issn | 1013-9087 2005-3894 |
| language | kor |
| recordid | cdi_kiss_primary_3971421 |
| source | KoreaMed Synapse; KoreaMed Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Alopecia Androgenic alopecia Dutasteride Epidemiology Finasteride Retrospective studies |
| title | Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T09%3A14%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Effectiveness%20and%20Safety%20of%20Dutasteride%20versus%20Finasteride%20in%20Patients%20with%20Male%20Androgenic%20Alopecia%20in%20South%20Korea:%20A%20Multicentre%20Chart%20Review%20Study&rft.jtitle=Annals%20of%20dermatology&rft.au=Gwang-seong%20Choi&rft.date=2022-10-05&rft.volume=34&rft.issue=5&rft.spage=349&rft.pages=349-&rft.issn=1013-9087&rft.eissn=2005-3894&rft_id=info:doi/&rft_dat=%3Ckiss%3E3971421%3C/kiss%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=3971421&rfr_iscdi=true |